Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis.
Aarts MJ, Vriens BE, de Boer M, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Tol J, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, van der Rijt CCD, Smilde TJ, van der Velden AW, Peer N, Tjan-Heijnen VCG. Aarts MJ, et al. Among authors: stouthard jm. Oncology. 2017;93(5):323-328. doi: 10.1159/000479067. Epub 2017 Aug 22. Oncology. 2017. PMID: 28848182
Response to influenza virus vaccination during chemotherapy in patients with breast cancer.
Meerveld-Eggink A, de Weerdt O, van der Velden AMT, Los M, van der Velden AWG, Stouthard JML, Nijziel MR, Westerman M, Beeker A, van Beek R, Rimmelzwaan GF, Rijkers GT, Biesma DH. Meerveld-Eggink A, et al. Ann Oncol. 2011 Sep;22(9):2031-2035. doi: 10.1093/annonc/mdq728. Epub 2011 Feb 8. Ann Oncol. 2011. PMID: 21303799 Free article. Clinical Trial.
Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC. Aarts MJ, et al. Among authors: stouthard jm. J Clin Oncol. 2013 Dec 1;31(34):4290-6. doi: 10.1200/JCO.2012.44.6229. Epub 2013 Apr 29. J Clin Oncol. 2013. PMID: 23630211 Clinical Trial.
Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC. Aarts MJ, et al. Among authors: stouthard jm. J Clin Oncol. 2013 Dec 1;31(34):4283-9. doi: 10.1200/JCO.2012.48.3644. Epub 2013 Oct 28. J Clin Oncol. 2013. PMID: 24166522 Clinical Trial.
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
Hamberg P, Bos MM, Braun HJ, Stouthard JM, van Deijk GA, Erdkamp FL, van der Stelt-Frissen IN, Bontenbal M, Creemers GJ, Portielje JE, Pruijt JF, Loosveld OJ, Smit WM, Muller EW, Schmitz PI, Seynaeve C, Klijn JG; Dutch Breast Cancer Trialists' Group (BOOG). Hamberg P, et al. Among authors: stouthard jm. Clin Breast Cancer. 2011 Apr;11(2):103-13. doi: 10.1016/j.clbc.2011.03.003. Epub 2011 Apr 11. Clin Breast Cancer. 2011. PMID: 21569996 Clinical Trial.
Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients.
Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, van Galen A, Peeters DJ, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, Stouthard JM, Kehrer DF, Look MP, Smid M, Gratama JW, Foekens JA, Martens JW, Sleijfer S. Mostert B, et al. Among authors: stouthard jm. Ann Oncol. 2015 Mar;26(3):510-6. doi: 10.1093/annonc/mdu557. Epub 2014 Dec 3. Ann Oncol. 2015. PMID: 25471333 Free article. Clinical Trial.
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH, Stouthard JM, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). van Ramshorst MS, et al. Among authors: stouthard jm. Breast. 2016 Oct;29:153-9. doi: 10.1016/j.breast.2016.07.017. Epub 2016 Aug 5. Breast. 2016. PMID: 27498129 Clinical Trial.
39 results